Vivos Therapeutics, Inc.
Qualité des données : 100%
VVOS
NASDAQ
Manufacturing
Measuring & Analyzing Instruments
1,47 €
▲
0,12 €
(8,89%)
6 months return
—
Momentum
Neutral
5Y revenue growth
3,56%
Croissance
Revenue Growth (5Y)
3,56%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)8,91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-480,76%
En dessous de la moyenne du secteur (-54,68%)
ROIC-68,18%
Net Margin-98,76%
Op. Margin-94,23%
Sécurité
Debt / Equity
3,31
Au-dessus de la moyenne du secteur (0,30)
Current Ratio0,78
Interest CoverageN/A
Valorisation
PE (TTM|NTM)
-0,84 | -0,97
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio5,65
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue grew 3,56% annually over 5 years — modest growth
Debt/Equity of 3,31 — high leverage
Negative free cash flow of -15,37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5,35%
Capital efficient — spends only 5,63% of revenue on capex
Price History
Tendances Financières
Objectif de Cours des Analystes
3 analystes
Buy
+240.1%
upside to target
Actuel
1,47 €
Consensus Target
5,00 €
2,50 €
Bas
7,00 €
Haut
Prévisions
P/E Prévisionnel
-0,97
BPA Prévisionnel
-1,25 €
CA Est.
28,96 M
Surprises de Résultats
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -0,42 €
·
Rev Est: 6,25 M
| Q42024 | Q12025 | Q22025 | Q32025 | Q1 '26 | |
|---|---|---|---|---|---|
| Reported | -0,28 € | -0,45 € | -0,55 € | -0,49 € | — |
| Estimate | -0,43 € | -0,40 € | -0,38 € | -0,51 € | -0,42 € |
| Surprise | +34,88% | -12,50% | -44,74% | +3,92% | — |
Growth
Rev 5Y: 3,56% · Earnings 1Y: N/A
Growth
Rev 5Y: 3,56% · Earnings 1Y: N/A| Revenue Growth (1Y) | 8,91% | Revenue Growth (3Y) | -3,15% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 3,56% | Earnings Growth (5Y) | N/A |
Profitability
ROE: -480,76% · Net Margin: -98,76%
Profitability
ROE: -480,76% · Net Margin: -98,76%| Revenue (TTM) | 17,32 M | Net Income (TTM) | -17,10 M |
| ROE | -480,76% | ROA | -66,19% |
| Gross Margin | 55,73% | Operating Margin | -94,23% |
| Net Margin | -98,76% | Free Cash Flow (TTM) | -15,37 M |
| ROIC | -68,18% | FCF Growth (3Y) | N/A |
Safety
D/E: 3,31 · Current: 0,78
Safety
D/E: 3,31 · Current: 0,78| Debt / Equity | 3,31 | Current Ratio | 0,78 |
| Interest Coverage | N/A | Asset Turnover | 0,67 |
| Working Capital | -1,65 M | Tangible Book Value | -8,09 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -0,84 · EV/EBITDA: N/A
Valuation
P/E: -0,84 · EV/EBITDA: N/A| P/E Ratio | -0,84 | Forward P/E | -0,97 |
| P/B Ratio | 5,65 | P/S Ratio | 0,83 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,49 | Fwd Earnings Yield | N/A |
| FCF Yield | -107,43% | ||
| Market Cap | 14,30 M | Enterprise Value | 19,60 M |
Per Share
EPS: -1,77 · FCF/Share: -1,30
Per Share
EPS: -1,77 · FCF/Share: -1,30| EPS (Diluted TTM) | -1,77 | Revenue / Share | 1,46 |
| FCF / Share | -1,30 | OCF / Share | -1,22 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 89,84% · CapEx/Rev: 5,63%
Efficiency
FCF Conv: 89,84% · CapEx/Rev: 5,63%| CapEx / Revenue | 5,63% | FCF Conversion | 89,84% |
| SBC-Adj. FCF | -16,12 M | Growth Momentum | 5,35 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 15,03 M | 13,80 M | 16,02 M | 16,89 M | 13,07 M |
| Net Income | -11,14 M | -13,58 M | -23,85 M | -20,29 M | -12,06 M |
| EPS (Diluted) | -2,22 | -11,14 | — | — | — |
| Gross Profit | 9,02 M | 8,27 M | 10,02 M | 12,60 M | 10,41 M |
| Operating Income | -11,17 M | -17,30 M | -25,03 M | -20,38 M | -12,04 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 100 000,0 | 100 000,0 | 200 000,0 | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 581 000,0 | 621 000,0 | 669 000,0 | 733 000,0 | 717 865,0 |
| Interest Expense | — | — | 14 000,0 | 14 000,0 | 96 681,0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 15,28 M | 10,73 M | 13,72 M | 33,69 M | 25,33 M |
| Total Liabilities | 7,33 M | 10,32 M | 8,92 M | 8,15 M | 8,41 M |
| Shareholders' Equity | 7,95 M | 411 000,0 | 4,80 M | 25,54 M | 16,92 M |
| Total Debt | — | — | — | 1,27 M | 1,29 M |
| Cash & Equivalents | 6,26 M | 1,64 M | 3,52 M | 24,03 M | 18,21 M |
| Current Assets | 7,47 M | 2,46 M | 5,42 M | 27,32 M | 20,39 M |
| Current Liabilities | 4,98 M | 7,29 M | 6,81 M | 7,51 M | 7,82 M |
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs)
Par rapport à des entreprises similaires dans Manufacturing
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs) Par rapport à des entreprises similaires dans Manufacturing| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -0,8 | -1,5 |
| P/B | 5,7 | 1,6 |
| ROE % | -480,8 | -54,7 |
| Net Margin % | -98,8 | -41,5 |
| Rev Growth 5Y % | 3,6 | 1,8 |
| D/E | 3,3 | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"VVOS","listing_kind":"stock","pathname":"/stocks/vvos","exchange":"NASDAQ","country":"US"}}